THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Thursday, August 13, 2026
Oral dissolvable strip technology solutions are being shaped by manufacturing complexity as pharmaceutical companies move from promising concepts to commercial products. The format looks simple to patients, but producing a thin film with uniform dosing, acceptable taste and reliable stability requires disciplined process control.
Orodispersible films are manufactured using several methods, from large-scale production to small-scale personalized preparation. A Pharmaceutics review notes that both ODF products and fabrication methods have limitations. At the same time, ongoing work by pharmaceutical companies and academic centers is focused on new formulations and improved manufacturing approaches.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Every strip needs to contain the intended amount of the active pharmaceutical ingredient. Achieving that depends on keeping the film uniform from one end of the production run to the other. Variations can affect the dose a patient ultimately receives, which is why regulators place such strong emphasis on dose uniformity during pharmaceutical manufacturing.
The formulation often determines how an oral film is manufactured. Techniques such as solvent casting and hot-melt extrusion are widely used, but neither is the right answer in every situation. The properties of the polymer and the active ingredient play a major role in that decision, particularly when the formulation includes compounds that are sensitive to heat.
Packaging also becomes a critical part of the technology. A recent formulation and manufacturing review notes that orodispersible films can require specialized and costly packaging because they may disintegrate quickly during production and storage. This raises the bar for providers that want to support commercial-scale products.
An oral film begins working in the mouth, which means patients notice its taste immediately. If the formulation is bitter or causes irritation, it can affect how readily people accept the product. Addressing that challenge requires careful formulation so that flavoring and sweetening improve the patient experience without interfering with drug release, stability or overall performance. The balance is especially important for products intended for children and older adults.
Scale-up can expose weaknesses that were not visible in early development. A formulation that works in a lab batch may face problems when film width, drying conditions, cutting accuracy and packaging speed increase. Providers with experience in process transfer can help pharmaceutical clients avoid expensive delays.
Not every oral dissolving film that reaches the market stays there. A recent state-of-the-art review found that although the number of commercially available products continues to grow, some have been withdrawn because of manufacturing constraints and commercial viability challenges. It is a reminder that technical success alone is not enough. A product also needs to make sense from a business perspective.
Quality systems will become a differentiator. Pharmaceutical customers need partners that can support validation, stability testing, regulatory documentation and batch-to-batch consistency. A technology provider that focuses only on formulation creativity may struggle when clients move toward approval or launch.
The next phase of the market will likely favor companies that understand the full strip lifecycle. That includes formulation design, manufacturing scale-up, packaging strategy and quality documentation.
Oral dissolvable strip technology solutions are becoming manufacturing-intensive platforms. Their strongest providers will be those that make the format commercially reliable, not only scientifically interesting.
More in News